Alzheimer's Disease
Conditions
Keywords
Alzheimer's disease, SPECT
Brief summary
This is a Phase 1, single center, open-label, non-randomized, clinical study in probable AD patients and HVs to evaluate the efficacy, safety and tolerability of a single dose of MNI-672. The underlying goal of this study is to assess MNI-672 SPECT imaging as a tool to detect ß amyloid deposition in the brain of AD research participants and young healthy male subjects. All study procedures will be conducted at Molecular NeuroImaging (MNI) in New Haven, CT. Approximately 3 patients with AD and 3 young male HVs will be recruited to participate in this study. HVs will be screened to ensure that there is no evidence of cognitive decline or significant neurological deficit. All eligible subjects will be required to visit the study center on at least 2 occasions: 1. for one or more screening visits which should include a history and physical examination, laboratory and extensive neuro-psychological testing and MRI brain scanning. AD subjects will also undergo Amyvid PET imaging as part of the Screening Visit. 2. on one day for baseline examinations and MNI-672 administration and subsequent SPECT scanning- followed by safety measures
Detailed description
To determine diagnostic efficacy of the MNI-672 SPECT scans in differentiating between patients with probable AD and HVs on the basis of neocortical tracer binding pattern, the SPECT scans will be visually assessed by a nuclear physician experienced in the field of neuro-imaging. SPECT scan findings will be classified either as abnormal (i.e., significant neocortical uptake in predefined regions) or as normal (i.e. no significant neocortical uptake in predefined regions). The visual analysis of the MNI SPECT images will be compared to the clinical diagnosis and Amyvid PET imaging results to determine the efficacy of MNI-672 as an agent to detect B-amyloid. The nuclear physician evaluating the SPECT images will be unaware of the clinical diagnosis.
Interventions
DRUG[123I]MNI-672 SPECT
Subjects will be dosed by intravenous injection to a target dose of 5 mCi and not to exceed 5.5 (not \>10% of 5 mCi limit) I-123 MNI-672 prior to the SPECT scan.
Sponsors
Molecular NeuroImaging
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
20 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
Healthy Volunteer Inclusion Criteria: * is male and is 20-30 years of age (inclusive) * has no evidence of cognitive impairment as indicated by a clinical dementia rating (CDR, \[Hughes et al. 1993\]) score of 0 (zero) and a score of ≥ 28 in the Mini-Mental Status Examination (MMSE, \[Folstein et al. 1975\]) * has MRI brain scan that has been judged as normal (age- appropriate) including ARWMC scale \[Wahlund et al. 2001\] scores supporting the lack of cerebrovascular disease (e.g., a white matter lesion score of 0 or 1 or 2 and a basal ganglia score of 0 or 1) * has no family history of AD defined by more than 1 first-degree relative Alzheimer disease subject inclusion criteria: * is male or female and is ≥ 50 of age, whereby females must be without childbearing potential (confirmed by either: age ≥ 60; or history of surgical sterilization or of hysterectomy, or last spontaneous bleeding at least 2 years prior to the study start) * presents with positive assessment for dementia of Alzheimer's type in accordance with the DSM-IV-TR and probable AD according to the NINCDS-ADRDA criteria and fulfils none of the
Exclusion criteria
of either * does not fulfill the ICC criteria for probable DLB, the NINDS-AIREN for probable Vascular dementia, or the Neary \[Neary et al. 1998\] criteria for FTD * has a CDR \[Hughes et al. 1993\] score of 0.5, 1 or 2 * MRI brain scan findings that do not reveal changes indicative of stroke and/or generalized cerebrovascular disease (e.g., the ARWMC scale) changes limited to: a white matter lesion score of 0 or 1 or 2 and a basal ganglia score of 0 or 1) * has an Amyvid PET scan with moderate to frequent amyloid neuritic plaques based on visual interpretation * has a caregiver who is willing and able to attend study visits and perform the psychometric tests requiring the presence of a caregiver
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Clinically significant changes in vital signs | 2 years | Safety will also be assessed by any clinically significant changes in vital signs, ECG parameters, physical examination findings, clinical laboratory findings, and injection site monitoring. |
| Number of subjects with adverse events | 2 years | Safety will be assessed by the number of participants with adverse events. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Total I-123 radioactivity in plasma | 2 years | The plasma concentrations will be expressed in %ID/mL. The I-123 radioactivity will be derived from the concentration -time profile. |
| Standard uptake values (SUV) | 2 years | Standard uptake values (SUV) for the target areas including the frontal cortex, temporal cortex, parietal cortex, posterior cingulate cortex and anterior cingulate cortex, and the cerebellum as the reference region will be calculated. Standard uptake values regional (SUVR) for cortical target areas relative to cerebellum will also be calculated. |
| Visual analysis | 2 years | The imaging diagnosis will be compared to the clinical diagnosis and Amyvid PET interpretation to determine the efficacy of MNI-672 as a diagnostic tool for AD. |
Countries
United States
Outcome results
None listed